REGN 2810

Drug Profile

REGN 2810

Alternative Names: PD-1 protein inhibitor - Regeneron; REGN2810; SAR 439684

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Basal cell cancer; Small cell lung cancer
  • Phase I B cell lymphoma; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 03 Aug 2017 Regeneron Pharmaceuticals plans a phase III trial for Cervical cancer in 2017
  • 27 Jun 2017 Phase-I clinical trials in Cancer (Monotherapy, Late-stage disease) in Japan (IV) (NCT03233139)
  • 23 Jun 2017 Sanofi plans the phase I/II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada and USA (NCT03194867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top